SCYNEXIS, Inc. (SCYX)
NASDAQ · Manufacturing · Pharmaceutical preparations
SCYX price, last 12 months
Key stats
- Previous close
- $2.61
- Open
- $2.59
- Day range
- $2.30 – $2.74
- 52-week range
- $2.30 – $9.12
- Volume
- 156K
- Avg volume (20 days)
- 76.3K
- Market cap
- $31.9M
Performance
Technicals and fundamentals
About SCYNEXIS, Inc.
SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against broad range of Candida and Aspergillus species, including drug-resistant strains as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and some common mucorales species.
- Sector
- Manufacturing
- Industry
- Pharmaceutical preparations
- Listed on
- NASDAQ
- Market cap
- $31.9M